Key result
The EUROASPIRE Risk Model successfully predicted recurrent cardiovascular events, which occurred in 11.4% (1,424 of 12,484) of patients with coronary heart disease over a median of 1.7 years.
Why the study?
Recurrent event risk varies widely among patients with established atherosclerotic CVD, creating a need to identify those who may benefit from more intensive secondary prevention strategies.
Cohort (n=12,484)
Yes
The EUROASPIRE Risk Calculator provides a validated tool to estimate 1- and 2-year risk of recurrent cardiovascular events in patients with stable coronary heart disease, helping to guide intensive secondary prevention.
May support risk stratification in stable CHD; leaves open whether model use improves outcomes.
AIMS: Most patients with established atherosclerotic cardiovascular disease (CVD) are at very high risk for developing recurrent events. Since this risk varies a lot between patients there is a need to identify those in whom an even more intensive secondary prevention strategy should be envisaged. Using data from the EUROASPIRE IV and V cohorts of coronary heart disease (CHD) patients from 27 European countries, we aimed at developing and internally and externally validating a risk model predicting recurrent CVD events in patients aged < 75 years. METHODS AND RESULTS: Prospective data were available for 12 484 patients after a median follow-up time of 1.7 years. The primary endpoint, a composite of fatal CVD or new hospitalizations for non-fatal myocardial infarction (MI), stroke, heart failure, coronary artery bypass graft, or percutaneous coronary intervention (PCI), occurred in 1424 patients. The model was developed based on data from 8000 randomly selected patients in whom the association between potential risk factors and the incidence of the primary endpoint was investigated. This model was then validated in the remaining 4484 patients. The final multivariate model revealed a higher risk for the primary endpoint with increasing age, a previous hospitalization for stroke, heart failure or PCI, a previous diagnosis of peripheral artery disease, self-reported diabetes and its glycaemic control, higher non-high-density lipoprotein cholesterol, reduced renal function, symptoms of depression and anxiety and living in a higher risk country. The model demonstrated excellent internal validity and proved very adequate in the validation cohort. Regarding external validity, the model demonstrated good discriminative ability in 20 148 MI patients participating in the SWEDEHEART register. Finally, we developed a risk calculator to estimate risks at 1 and 2 years for patients with stable CHD. CONCLUSION: In patients with CHD, fatal and non-fatal rates of recurrent CVD events are high. However, there are still opportunities to optimize their management in order to prevent further disease or death. The EUROASPIRE Risk Calculator may be of help to reach this goal.
No takes yet. Share an insight, caveat, or question.
Bacquer et al. (2020) conducted a cohort in coronary heart disease (n=12,484). Multiple clinical risk factors (age, prior hospitalizations, diabetes, non-HDL cholesterol, renal function, depression/anxiety) was evaluated on Composite of fatal CVD or new hospitalizations for non-fatal myocardial infarction (MI), stroke, heart failure, coronary artery bypass graft, or percutaneous coronary intervention (PCI). The EUROASPIRE Risk Model successfully predicted recurrent cardiovascular events, which occurred in 11.4% (1,424 of 12,484) of patients with coronary heart disease over a median of 1.7 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: